| Identification | Back Directory | [Name]
1V209 | [CAS]
1062444-54-5 | [Synonyms]
1V209
TLR7 agonist T7
1V209(TLR7 agonist T7)
TLR7 agonist T7 (1V209)
4-((6-Amino-2-(2-methoxyethoxy)-8-oxo-7，8-dihydro-9H-purin-9-yl)methyl)benzoic acid
Benzoic acid, 4-[[6-amino-7,8-dihydro-2-(2-methoxyethoxy)-8-oxo-9H-purin-9-yl]methyl]- | [Molecular Formula]
C16H17N5O5 | [MDL Number]
MFCD32667006 | [MOL File]
1062444-54-5.mol | [Molecular Weight]
359.34 |
| Chemical Properties | Back Directory | [density ]
1.466±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 83.33 mg/mL (231.90 mM) | [form ]
Solid | [pka]
4.23±0.10(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity[1][2]. | [in vivo]
The intravenous (IV) administration of the formulation to mice bearing 4T1 breast cancer tumors results in nanoparticle accumulation in tumors, reduction in primary tumor growth, and inhibition of lung metastases, as compared to saline-treated animals. Mice administered 1V209 experience significantly increases plasma levels of proinflammatory cytokines IL-6, IP-10, and MCP-1 at 2 h following IV administration[1]. | [IC 50]
TLR7 | [References]
[1] Battistella C, et al. Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. Adv Healthc Mater. 2019 Dec;8(23):e1901105. DOI:10.1002/adhm.201901105
[2] Shinchi H, et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjug Chem. 2015 Aug 19;26(8):1713-23. DOI:10.1021/acs.bioconjchem.5b00285 |
|
| Company Name: |
Shanghai GL Peptide Ltd.
|
| Tel: |
+86-21-61263340; 17609490614 13764994101 |
| Website: |
https://www.chemicalbook.com/supplier/10480342/ |
|